Evaluating Testosterone Therapy to Prevent Heart Failure in Women: The ETHEL study.

Monash University0 个研究点目标入组 38 人开始时间: 2023年2月17日最近更新: 2023年2月27日

适应症

试验速览

暂无简介。

•Evidence of Stage B heart failure with reduced functional capacity (<85% age-predicted VO2peak).
•- Normal mammogram within the preceding 2 years

•- Heart failure, either documented or undiagnosed with an EF <40% or NTproBNP >400ng/L
•- Other cardiac disease (myocardial infarction, angina; known coronary artery disease; valve disease more than moderate)
•- Features incompatible with the study design (unlikely to be adherent to follow-up; <12 months life expectancy due to concomitant disease; participation in another clinical trial where blinded treatment would be unacceptable; unable to provide written informed consent)
•- Inability to acquire interpretable echo images (uncommon)
•- Unstable diabetes (HbA1C>7.5%)
•- Estrogen-sensitive cancer
•- Use of any drugs or dietary supplements that may affect testosterone effects including, but not limited to systemic antiandrogen therapy (spironolactone; cyproterone acetate; finasteride; minoxidil)
•- Treatment with SGLT-2 inhibitors or GLP-1 agonists as indicated
•- Recent use of androgen therapy
•- Contraindication to exercise
•- Inability to speak or understand English

发起方